Skip to main content
. 2013 Sep 3;31(33):4179–4187. doi: 10.1200/JCO.2013.49.2173

Table 2.

Incidence of SPTs by Treatment Arm (252 SPTs observed in 224 patients)

Site of SPT Placebo
Selenium
No. % No. %
Breast 2 2.4 8 4.7
Colon 3 3.6 3 1.8
Rectum 1 1.2 1 0.6
Gastric 0 0.0 1 0.6
Pancreas 3 3.6 5 3.0
Esophagus 0 0.0 1 0.6
Liver, gallbladder, bile duct 0 0.0 6 3.6
Small Intestines 0 0.0 1 0.6
Head and neck 2 2.4 4 2.4
Thyroid 2 2.4 2 1.2
Myeloma 0 0.0 2 1.2
Chronic lymphocytic leukemia 1 1.2 1 0.6
Acute non–lymphocytic leukemia, AML 1 1.2 0 0.0
Chronic myelogenous leukemia 0 0.0 1 0.6
Myelodysplastic syndrome 1 1.2 4 2.4
Lung cancer 23 28.1 58 34.1
Small-cell lung 3 3.6 3 1.8
Non–small-cell lung 2 2.4 9 5.4
Melanoma 2 2.4 5 3.0
Basal cell carcinoma 13 15.9 14 8.3
Skin cancer not melanoma 6 7.2 11 6.6
Kaposi's sarcoma 1 1.2 0 0.0
Bladder, urinary tract 6 7.3 9 5.2
Prostate 9 11.0 16 9.5
Cervix 0 0.0 1 0.6
Chest wall 0 0.0 1 0.6
Vocal cord 1 1.2 0 0.0
Inguen (groin) 0 0.0 1 0.6
Left groin lymph node 0 0.0 1 0.6
Unknown 1 1.2 0 0.0
Total 83 169

Abbreviations: AML, acute myeloid leukemia; SPT, second primary tumor.